– May 1, 2008
May 1, 2008
View Issues
-
Parenteral Iron Improves Darbepoetin Responses in Non-Iron Deficient Chemotherapy Treated Patients
In a randomized, prospective trial, anemic chemotherapy-receiving patients received either darbepoetin alone or darbepoetin with intravenous ferric gluconate. The group that received the added ferric gluconate had a significantly higher rate of achieving objective criteria for anemia improvement. The iron infusions were associated with no observed toxicity. -
Anti-IL-5 Therapy for Hypereosinophilic Syndrome (HES)
Hypereosinophilic syndrome (HES) is a spectrum of diseases where a primary cause of eosinophilia can not be identified. -
CA 15-3 and CEA: Not So Novel, But Useful Breast Cancer Tumor Markers
In a retrospective analysis of 740 patients with stage I-III breast cancer, preoperative serum levels of CA 15-3 and CEA were both shown to relate to important clinical outcomes, including disease-free and overall survival. -
Anemia and Local Recurrence of Breast Cancer
For premenopausal ER+ breast cancer patients receiving CMF chemotherapy in an adjuvant setting, the presence of anemia during treatment was found to be a significant risk factor for the development of local recurrence. -
CA125 Validity a Concern for Assessing Ovarian Cancer Responses to Molecularly Targeted Therapies
In a pilot study of ovarian cancer patients treated with sorafenib and bevacizumab, CA125 concentrations were shown to not correspond with imaging analyses in the assessment of treatment response. Thus, caution is raised about using this tumor marker alone in the assessment of treatment outcomes for patients treated with newer, molecularly-targeted therapies. -
Clinical Briefs in Primary Care supplement
-
Pharmacology Watch
FDA drug approval to change? Urinary incontinence in women; how metabolism of certain drugs can be predicted by genetic analysis; bowel preps may compromise renal function especially in the elderly according to a new study; FDA Actions.